Bcl9L Antibody

Product Specifications

Background

Bcl9L Antibody: Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF) -mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.

NCBI Gene ID

283149

Swiss Prot

Q86UU0

Accession Number

NP_872363

Host

Rabbit

Reactivity

Human

Clonality

Polyclonal

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Cancer, Cell Cycle

Purification

Bcl9L Antibody is affinity chromatography purified via peptide column.

Positive Control

Cat. No. 1201 - HeLa Cell Lysate

Concentration

1 mg/mL

Homology

Predicted species reactivity based on immunogen sequence: Mouse: (100%), Rat: (100%)

Buffer

Bcl9L Antibody is supplied in PBS containing 0.02% sodium azide.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Bcl9L antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Fragment

IgG

Specificity

Bcl9L antibody is predicted to not cross-react with other Bcl family members. At least four isoforms of Bcl9L are known to exist; this antibody will detect all four.

Symbol

BCL9L

Positive Control 2

Cat. No. 17-001 - HeLa Cell Slide

NCBI Official Name

B-cell CLL/lymphoma 9-like

NCBI Organism

Homo sapiens

Background Reference 01

Katoh M and Katoh M. Identification and characterization of human BCL9L gene and mouse Bcl9l gene in silico. Int. J. Mol. Med. 2003; 12:643-9.

Background Reference 02

Adachi S, Jigami T, Yasui T, et al. Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling. Cancer Res. 2004; 64:8496-501.

Background Reference 03

Toya H, Oyama T, Ohwada S, et al. Immunohistochemical expression of the beta-catenin-interacting protein B9L is associated with histological high nuclear grade and immunohistochemical ErbB2/HER-2 expression in breast cancers. Cancer Sci. 2007; 98:484-90.

Background Reference 04

Deka J, Wiedemann N, Anderle P, et al. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinoma. Cancer Res. 2010; 70:6619-28.